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Abstract
Background Castration-resistant prostate cancer is a disease
with limited treatment options. However, the ongoing
elucidation of the mechanisms underlying this disease con-
tinues to support the development of not only novel agents,
but also innovative approaches. Among these therapies,
immunotherapy has emerged as a promising strategy.
Design This review article summarizes the most recent data
from investigations of immunotherapies in castration-
resistant prostate cancer (literature and congress searches
current as of August 2011).
Results Immunotherapeutic strategies such as passive im-
munization, vaccines, and particularly checkpoint blockade
have demonstrated some efficacy as single agents. Eluci-
dation of effective combinations of agents and drug
regimens is ongoing but will require continued careful
investigation, including the standardization of surrogate
endpoints in clinical trials.
Conclusions It is hypothesized that the combination of
immunotherapeutic agents with traditional and novel
chemotherapeutics will potentiate the efficacy of the
chemotherapeutics while maintaining manageable toxicity.
Keywords Biochemotherapy . castration-resistant prostate
cancer . chemotherapy . hormone-refractory prostate cancer .
immunotherapy
Introduction
Prostate cancer is the most common nonskin cancer in
males in the USA. In 2009, an estimated 192,280 cases
were diagnosed, with 27,360 deaths attributed to the disease
[1]. Certain low-risk cases of clinically localized prostate
cancer can be managed by active surveillance, but most
patients are initially managed with radiotherapy (external
beam and interstitial), radical prostatectomy, or cryosurgery
[2]. Advanced prostate cancer requires androgen depriva-
tion therapy (ADT) as the standard of care. However,
although the majority of men initially respond to ADT,
most tumors become resistant to primary hormone therapy,
with a median time to androgen independence of 14 to
30 months [3]. Castration-resistant prostate cancer (CRPC)
is defined as progressive disease in a patient with a castrate
level of testosterone [4]. For men with CRPC, chemother-
apy with docetaxel has been proven to extend survival and
is considered standard of care for patients [5, 6]. In 2010,
the autologous cellular immunotherapeutic sipuleucel-T
(PROVENGE®, Dendreon Corporation, Seattle, WA,
USA) also received Food and Drug Administration (FDA)
approval in patients with asymptomatic or minimally
symptomatic metastatic CRPC based on a survival advan-
tage in phase III testing, and this approval provides firm
proof of principal for immunotherapy in CRPC. Cabazi-
taxel (JEVTANA®, Sanofi-aventis, Bridgewater, NJ, USA),
a microtubule inhibitor, was also approved by the US FDA
in 2010 to be used in combination with prednisone for
treatment of patients with CRPC previously treated with a
docetaxel-containing treatment regimen. In addition to
these interventions, significant clinical research has been
directed at identifying novel therapies that prolong survival
while maintaining quality of life of patients with CRPC,
and it is predicted that this body of research will continue to
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augment the treatment options available to these men. This
review will provide a background of the strategies that are
currently under development for CRPC (including chemo-
therapy, radiotherapy, and immunotherapy), followed by a
discussion about immunotherapy-focused combination
approaches and important considerations for clinical trial
development of these strategies.
Nonimmunotherapeutic Options for CRPC
The goal of current treatments for CRPC is to stop or slow
the growth of cancer cells in order to prolong patient
survival without negatively affecting their quality of life.
Mitoxantrone was the first chemotherapeutic agent that
demonstrated clinical activity in CRPC, approved in 1996
based on an improvement in quality of life [7]. Two
landmark trials, SWOG9916 and TAX327, which com-
pared mitoxantrone against docetaxel, established docetaxel
as the current standard of care for patients for whom
chemotherapy is indicated. These trials showed improve-
ments in time-to-progression (TTP), prostate-specific anti-
gen (PSA) response, a lowered hazard ratio (HR) for death,
and an improved survival benefit in the docetaxel arms [5,
6], which led to US FDA approval for docetaxel-based
therapy for CRPC.
Cabazitaxel was studied in the phase III TROPIC study
(N=755), which compared the safety and efficacy of
cabazitaxel plus prednisone (CP) to mitoxantrone plus
prednisone (MP) in the treatment of CRPC, which had
progressed after docetaxel use. Treatment with CP reduced
the risk of death by 30% (HR=0.70; p<0.0001) [8]. There
was a statistically significant benefit in median overall
survival (OS) in the CP group (15.1 months for the CP
group compared with 12.7 months in the MP group) [8]. A
phase III study is presently underway to compare OS with
differing doses of CP in metastatic CRPC patients, post-
docetaxel chemotherapy (NCT01308580). Additionally, a
second phase III study is evaluating OS in chemotherapy-
naive metastatic CRPC patients treated with two different
doses of CP regimen, in comparison with a third arm where
patients will receive docetaxel and prednisone therapy
(NCT01308567).
An increased understanding of the molecular mecha-
nisms and pathways that control the development of CRPC
has led to the development of new therapeutic agents, some
general cytotoxic agents and others that are directed at key
targets of these pathways. Therapy with agents that
specifically target proteins that drive CRPC may have
fewer side effects than those caused by cytotoxic agents
like docetaxel. A myriad of treatment options are in
development but none have yet shown significant advan-
tages over docetaxel.
Therapies that target the androgen receptor (AR) axis
more efficiently (e.g., abiraterone, MDV3100) are promis-
ing agents in development for CRPC. Abiraterone acetate
(AA) is a potent steroidal inhibitor of CYP17 (17 alpha-
hydroxylase/C17,20-lyase), blocking two important enzy-
matic activities in the synthesis of testosterone. AA
(ZYTIGA™, Centocor Ortho Biotech Inc, Horsham, PA,
USA) was approved by the US FDA and is expected to be
approved by the European Medicines Agency also in 2011
for use in combination with prednisone in the treatment of
metastatic CRPC in men who have received prior docetaxel
chemotherapy. Recently, a pivotal randomized phase III
trial, comparing AA and prednisone versus prednisone
alone in CRPC patients who have progressed on docetaxel,
showed improvedOS in the AA armwith a median survival of
14.8 months compared with 10.9 months in the placebo arm
[9]. Improvements in radiographic progression-free survival
(rPFS), time to PSA progression, and PSA response rates
were also observed. A phase III study comparing AA plus
prednisone versus placebo plus prednisone is ongoing in
men with CRPC who are asymptomatic or minimally
symptomatic and chemotherapy-naive (NCT00887198).
MDV3100 is a small molecule AR antagonist that blocks
nuclear translocation of AR DNA binding [10]. Following
promising results from a phase I/II trial with MDV3100,
two large randomized, multicenter phase III trials are
currently underway, comparing MDV3100 versus placebo
in chemotherapy-refractory or -naive CRPC patients
(NCT00974311 and NCT01212991, respectively). An
interim analysis of the latter trial in 65 chemotherapy-
naive CRPC patients showed that the circulating tumor cell
(CTC) number, PSA level, and PSA response at 12 weeks
were significant predictors of rPFS [11].
TAK-700 is a nonsteroidal androgen synthesis inhibitor
of 17,20-lyase, which is a key enzyme in the production of
steroidal hormones. Currently, two phase III studies in
CRPC patients are underway, comparing the combination
of TAK-700 plus prednisone versus placebo and predisone
in both chemotherapy-naive (NCT01193244) and post-
chemotherapy (NCT01193257) settings. Additionally,
TOK-001, a dual antiandrogen and CYP17 inhibitor, is in
clinical development [12].
Other strategies for disrupting the AR signaling pathway
are in early stages of development for the treatment of
CRPC. These include inhibition of heat shock proteins,
such as HSP90 (required for the folding and stabilization of
the AR), and the use of histone deacetylase inhibitors to
suppress the transcription of AR and AR-related genes.
These agents have yet to show much antitumor activity but
further investigation in combination with other agents may
prove their clinical benefit.
Epothilones (e.g., ixabepilone, patupilone) inhibit cell
division by interfering with microtubule function and have
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shown promise in the treatment of CRPC. In a small phase
II trial of chemotherapy-naive CRPC patients receiving
ixabepilone (40 mg/m2) every 3 weeks, 14 (33%) achieved
a PSA decline [13]. In the responders, 72% had a >80%
decline in PSA, and 2 patients achieved an undetectable
PSA. Ixabepilone alone has demonstrated modest antitumor
activity in CRPC, and ongoing studies of this agent in
combination with other therapies may demonstrate activity
that exceeds that of ixabepilone monotherapy.
Prostate Cancer: An Attractive Target
for Immunotherapy
Unlike a chemotherapeutic agent that can take an immedi-
ate effect on its target, immunotherapy requires time for the
patient’s immune system to mount a response. Thus,
immunotherapy is well suited for a slow-growing disease
such as prostate cancer [14], in which it is reasonable to
allow time for a clinically meaningful immune response to
occur. Multiple proteins unique to the prostate can serve as
antigens, and immunotherapies that exploit these antigens
may be able to direct an immunologic response specifically
to a prostate tumor. Equally important is the fact that
prostate glands are infiltrated by CD4 and CD8 T-cell
populations that are oligoclonally expanded (which sug-
gests their presence is not random, but rather the result of a
specific antigenic stimulation) [15, 16]. Abundant preclinical
studies have shown that immunological responses in the
prostate are elicited by various therapies, including immune
checkpoint blockade and radiotherapy. Interestingly,
therapies to which prostate cancer is initially responsive, such
as hormonal manipulation and androgen withdrawal, have
been shown to induce T-cell infiltration in prostate glands and
tumors [15].
Currently, most studies are investigating the efficacy of
immunotherapy in patients with metastatic CRPC, a disease
in which many tumor-induced immunosuppressive mecha-
nisms have already been established. Biochemical recur-
rence, as evidenced by rising PSA levels after surgery or
androgen ablation, provides a unique opportunity for
immunological intervention before the immunosuppressive
mechanisms associated with advanced disease are in place.
Therefore, early intervention with immunotherapy and
other agents may prove to be more effective than currently
approved and tested strategies.
Emerging Immunotherapeutic Approaches for CRPC
Immunotherapy for CRPC is an active field of investiga-
tion. A large number of immunotherapy approaches are
being developed in prostate cancer with the goal of
inducing a specific T-cell response directed against the
tumor. Multiple tumor-associated antigens (e.g., PSA,
prostate-specific membrane antigen [PSMA], and prostatic
acid phosphatase [PAP]) have been identified as potential
targets for prostate immunotherapy. The two major
approaches of immunotherapy are passive (agent has
intrinsic immunologic activity) and active (agent is
designed to stimulate host’s immune response).
One example of passive immunotherapy is using radio-
labeled monoclonal antibodies against tumor-specific pro-
teins to target radiation directly to the tumor. Radiolabeled
J591 (monoclonal antibody directed against PSMA) using
the radionuclides yttrium-90 and lutetium-177 has demon-
strated manageable myelotoxicity, no significant nonhema-
tologic toxicity, excellent tumor targeting (both of soft
tissue and bone metastases), and preliminary evidence of
efficacy, including PSA declines and measurable disease
responses [17, 18]. A dose escalation phase II trial of
177Lu-J591 in 30 patients with metastatic CRPC reported 3
patients with ≥50% decline in PSA and 9 with ≥30%
decline with more responders at higher dose. As a result of
this therapy, nine patients required one to four platelet
transfusions [19]. The preliminary results in this small
clinical trial are being confirmed in ongoing studies of J591
as a monotherapy and in combination with docetaxel
(NCT00195039 and NCT00916123, respectively).
Vaccine-based therapies seek to directly stimulate a
specific immune reaction against a single or many tumor
antigens. While the methods vary, vaccine therapies aim to
drive a specific antitumor response without compromising
normal tissues [3]. The four main types of vaccines that
have been investigated for CRPC can be classified as viral
vector based, cell based, DNA vaccines, and autologous
(derived from a patient’s own tumor cells).
Viral vaccination is an approach in which a gene (e.g., that
encoding PSA) is inserted into a recombinant virus vector,
after which a patient is immunized with a live, attenuated
recombinant virus. A recombinant vaccinia virus, which was
widely applied for vaccination against smallpox, was modi-
fied to express PSA (rV-PSA; PROSTVAC™, Bavarian
Nordic A/S, Kvistgård, Denmark). The vaccine was well
tolerated and induced durable PSA level decreases in nearly
half of the patients tested [20, 21]. However, repeated doses
of rV-PSA were proven to be ineffective at inducing PSA-
specific T-cell populations, possibly due to an immune
response against the vaccinia virus [21]. Consequently, a
prime/boost vaccine strategy (PROSTVAC-VF) was tested
using vaccinia virus and fowlpox virus (which will infect but
will not replicate in mammalian cells and may allow for
prolonged gene expression as compared with vaccinia)
expressing human PSA. In this study, 64 patients were
randomized to 3 treatment cohorts; 45.3% of patients
remained free of PSA progression at 19.1 months and
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78.1% demonstrated clinical progression-free survival (PFS)
[22].
The PROSTVAC-VF vaccine was advanced by the
addition of three virally expressed T-cell costimulatory
molecules: B7-1, intercellular adhesion molecule-1, and
lymphocyte function-associated antigen-3 (TRICOM) [23].
A phase II study of 122 patients with CRPC was carried
out, where patients were randomized to placebo or
PROSTVAC-VF/TRICOM+granulocyte-macrophage
colony-stimulating factor (GM-CSF) treatments. GM-CSF,
a cytokine adjuvant, is frequently administered with
vaccines, since it promotes maturation and expression of
major histocompatibility complexes (MHCs) and costimu-
latory molecules by antigen-presenting cells (APCs), in
addition to recruiting granulocytes and augmenting T-cell
response [24]. In the trial, PFS was similar in the treatment
and placebo groups (p=0.6) [25]. However, at 3 years post-
study, 25 (30%) vaccine patients were alive compared with
7 (17%) control patients. Patients in the vaccine arm had a
longer median survival than those in the control arm (25.1
and 16.6 months, respectively; estimated HR=0.56; p=
0.0061). These results need to be confirmed in a larger
phase III study.
GVAX is a cell-based allogeneic vaccine consisting of
the LNCaP and PC-3 prostate cell lines genetically
engineered to secrete high levels of GM-CSF. These cells
are injected intradermally in order to initiate an antiprostate
immune response. A phase II dose escalation study in 80
men with CRPC showed that PSA stabilization occurred in
15 (19%) patients, and a >50% decline in PSA was seen in
1 patient [26]. Median survival times were 35.0 months in
the high-dose group, 20.0 months in the mid-dose group,
and 23.1 months in the low-dose group. The proportion of
patients who generated an antibody response to one or both
cell lines increased with dose and included 10 of 23 (43%)
in the low-dose group, 13 of 18 (72%) in the mid-dose
group, and 16 of 18 (89%) in the high-dose group (p=
0.002). Based on these observations, the highest dose was
used for further clinical studies. Two phase III trials were
designed to study GVAX in asymptomatic and symptomatic
men with metastatic CRPC. The Vaccine Immunotherapy
with Allogeneic Prostate Cancer Cell Lines (VITAL-1) trial
compared GVAX to prednisone plus docetaxel in men with
asymptomatic CRPC. This trial finished accrual of patients
and was terminated by Cell Genesys, Inc. because a futility
analysis indicated that there was <30% chance of achieving
a survival benefit. VITAL-2 compared the combination
of GVAX and docetaxel treatment with the use of
prednisone and docetaxel in symptomatic CRPC.
VITAL-2 was terminated in August 2008 due to an
imbalance in deaths in the two arms, with 67 deaths in
the GVAX and docetaxel arm compared with 47 in the
control group [27].
Other studies have examined DNA vaccines with PSA to
induce immune responses. DNA vaccines have the advan-
tage of ease of production and administration, as well as
lack of viral antigens that may generate an immune
response. However, a disadvantage with DNA vaccines
includes the inability of producing a strong immune
response due to low cellular transfection efficiency [3]. A
DNA vaccine encoding PAP is in the early stages of
development for the treatment of CRPC. A phase I/IIa dose
escalation trial of this vaccine coadministered intradermally
with the adjuvant GM-CSF was conducted in patients with
stage D0 prostate cancer (biochemical [PSA] recurrence
after definitive local therapy) [28]. Patients developed PAP-
specific T-cell immune response shortly after the treatment
course, as determined by enzyme-linked immunospot. The
median PSA doubling time was observed to increase from
6.5 months pretreatment to 8.5 months on-treatment (p=
0.033) and 9.3 months in the 1-year post-treatment period
(p=0.054). A minimal adverse event (AE) profile was
observed and a larger trial of clinical efficacy is warranted.
Additionally, the University of Wisconsin is currently
sponsoring a phase II pilot study to determine the safety
of serial intradermal vaccinations PAP with GM-CSF as an
adjuvant, as well as to determine if the vaccine generates
long-lived immune responses in patients with nonmetastatic
CRPC (NCT00849121).
Dendritic cells, which are widely distributed in nearly all
tissues, present antigens through their MHC class 1 and 2
receptors and thus can induce immune responses by
activating T cells to develop a potent antitumor response.
Autologous dendritic cells can be grown in vitro and
transfected with antigen, cytokines, or other agents before
reintroduction to the patient to direct an immune response
[3]. Sipuleucel-T (APC8015) is a widely used dendritic cell
vaccine comprised of peripheral blood mononuclear cells
(including APCs) and pulsed ex vivo with a proprietary
PAP–GM-CSF fusion protein. A phase III trial of 127 men
with CRPC randomized to APC8015 or placebo was
conducted [29]. Although treatment with sipuleucel-T did
not result in a statistically significant delay in TTP, there
was a statistically significant (p=0.01) survival advantage
of 4.5 months in an intent-to-treat analysis. A recent phase
III trial, Immunotherapy for Prostate Adenocarcinoma
Treatment compared sipuleucel-T with placebo in 512
men with CRPC [30]. The sipuleucel-T-treated group
demonstrated 22% reduction in the risk of death as
compared with the placebo group (HR=0.78; 95% confi-
dence interval, 0.61–0.098; p=0.03), which represented a
4.1-month (25.8 versus 21.7 months) increase in OS, the
primary study endpoint. The estimated 36-month rates of
survival were 32% and 23% for the sipuleucel-T and
placebo groups, respectively. AEs that were more frequent-
ly reported in the sipuleucel-T group than in the placebo
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group included chills (51%), fever (31.3%), and headache
(18.1%); these were grade 2 or less in all but 3.5% of
patients. Based on these results, this vaccine was approved
by the FDA for the treatment of men with asymptomatic or
minimally symptomatic CRPC.
Another type of immunotherapy utilizes immunomodu-
lators to affect immune responses. The goal of immuno-
modulation in CRPC is to stimulate the immune system to
attack prostate cancer cells. One such immunomodulator is
GM-CSF, a pluripotent cytokine that has manifold impact
on the immune system, including enhancing T-cell
responses. GM-CSF first showed efficacy in CRPC by
decreases in PSA levels leading to long-term disease
control in ~15% of treated patients [31, 32]. A study of
GM-CSF in combination with ipilimumab is discussed in
the “Combination Strategies” section.
Monoclonal antibodies that target proteins important in
modulating immune response represent another promising
type of immunotherapy for CRPC. Antibodies can be used
to block negative immunological checkpoints that impede
an effective immune response (such as cytotoxic T-
lymphocyte antigen-4 [CTLA-4] and programmed death-1
[PD-1]) or enhance stimulatory signals (like 41BB). The
goal of this “checkpoint blockade” therapy is to sustain and
boost an antitumor immune response by enabling the
patient’s immune system to overcome the innate regulatory
mechanisms that control immune responses.
Ipilimumab (YERVOY™, Bristol-Myers Squibb,
Princeton, NJ, USA) is an antibody directed against
CTLA-4, a key negative regulator of T cells [33] that
was approved in March 2011 by the US FDA for
metastatic melanoma treatment. In a presurgical clinical
trial, the antibody has been shown to lead to infiltration of
effector T cells into tumor tissues with concomitant
decreases in regulatory T cells, thus increasing the ratio
of effector to regulatory T cells within the tumor
microenvironment [34, 35]. In a pilot study involving 14
patients with metastatic CRPC, 2 patients had ≥50%
decline in PSA. The most common AEs observed with
ipilimumab use are related to its immune-based mecha-
nism of action; these AEs were usually inflammatory in
nature and different from AEs observed with chemotherapies
or other immunotherapies. The treatment was well tolerated in
all but one patient who developed a grade 3 rash/pruritus [36].
Given promising results of ipilimumab use in metastatic
CRPC patients from this and other phase I/II studies [36–39],
a randomized, double-blind, phase III trial to compare the
efficacy of ipilimumab versus placebo in patients with
metastatic chemotherapy-naive CRPC is currently underway,
where comparison of OS between the two groups is a
primary endpoint (NCT01057810).
PD-1 and its ligands PDL-1 and PDL-2 represent
another immune checkpoint pathway of noted clinical
interest. Early clinical testing has demonstrated that PD-1
blockade has considerable activity against a variety of
advanced solid tumors, including renal carcinomas [24, 39].
Two phase I trials examining the safety of a fully human
monoclonal anti-PD-1 antibody, MDX-1106 (NCT00441337
and NCT00730639), include advanced prostate cancer
patients, though no clinical responses have yet been reported
in prostate cancer patients in these trials [40, 41].
Combination Strategies
Although immunotherapy has shown promising responses
as monotherapy, we and others believe that combination
therapy with standard modalities and novel nonimmuno-
therapeutic, as well as immunotherapeutic agents, will be
necessary to provide improved antitumor responses and
clinical benefit. Multiple ongoing trials are testing various
combinations of the strategies discussed above. In the
immunotherapy arena, strategies that are the focus of
multiple clinical trials include combination of vaccines
and chemotherapy, vaccines and androgen ablation, immu-
notherapy and radiotherapy, and checkpoint blockade
agents (e.g., ipilimumab) with various treatments.
The combination of vaccine with chemotherapy has
demonstrated clinical benefit, albeit it in a small study.
CRPC patients (N=28) were randomized to receive either
vaccine (rV-PSA admixed with rV-B7.1 as a prime,
followed by rF-PSA booster) and weekly docetaxel or
vaccine alone [42]. Eleven patients who progressed on
vaccine alone crossed over to receive docetaxel at the time
of progression. Receiving the vaccine prior to treatment
with docetaxel enhanced survival, over that observed
historically with docetaxel treatment. An interesting sub-
analysis of two sipuleucel-T trials suggested that this
vaccine enhances the effect of docetaxel [43]. Among
patients who received sipuleucel-T followed by docetaxel,
the median survival was 34.5 months; patients who were on
placebo then docetaxel had a survival of 25.7 months and
patients treated with docetaxel alone had a median survival
of 20.2 months. Larger phase II trials to test combinations
of different vaccines and chemotherapeutic agents are
ongoing (NCT01194960 and NCT01145508).
Androgen ablation can have a stimulatory effect on the
immune response, including the infiltration of activated
CD4+ T cells into the prostate gland and the induction of
antigen-specific immune responses [15, 44]. Androgen
ablation is presently being evaluated in combination with
ipilimumab, compared with androgen ablation alone, in
advanced prostate cancer patients in a phase II trial with the
rationale that the two agents may act synergistically in that
androgen ablation induces an intense T-cell infiltrate in the
prostate and CTLA-4 blockade potentiates T-cell responses
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[45]. Initial results show that the concurrent administration
of ipilimumab with androgen ablation may be synergistic as
hypothesized, with patients in the combination therapy
group more likely to have undetectable PSA by 3 months
compared with the androgen ablation only group (55%
versus 38%) [45]. The timing of androgen ablation in
combination with other therapies may prove to be crucial.
One study demonstrated that responses to a combination of
vaccine therapy, GM-CSF, and interleukin-2, were better in
patients that received androgen ablation after receiving the
vaccine than in those who received it before vaccine
therapy [46]. The immunologic effect of radiotherapy in
patients with prostate cancer has recently been shown [47].
The mechanism is thought to involve the priming of an
antitumor immune response as irradiation induces a pro-
inflammatory response in which dying tumor cells expose
tumor antigens to infiltrating immune cells [48, 49]. A
randomized phase II trial tested the combination of a
poxviral vaccine encoding PSA and radiotherapy in patients
with clinically localized prostate cancer. Thirteen out of 17
patients in the combination arm had increases in PSA-
specific T cells of at least threefold versus no detectable
increases in the radiotherapy-only arm (p<0.0005) [50].
The combination of radiotherapy and the immunomodulator
ipilimumab is discussed below.
The checkpoint blockade agent ipilimumab is being
studied in combination with immunomodulators (GM-
CSF), vaccines (GVAX), radiotherapy, and chemotherapy.
GM-CSF in combination with ipilimumab was tested in 24
patients with CRPC [37]. In this study, three of six patients
treated at the highest level of ipilimumab had >50% PSA
declines; one of these patients showed partial response in
visceral metastases. This combination was shown to have
an immunostimulatory effect as it induced the expansion of
activated effector CD8 T cells in vivo. These results need to
be confirmed and the impact on survival should be
determined in a larger trial.
A phase I trial of GVAX in combination with ipilimu-
mab is underway and preliminary results show the therapy
is well tolerated and active in CRPC [51]. Twelve patients
were treated in a dose escalation phase for 24 weeks with
biweekly intradermal injections of GVAX and monthly
ipilimumab at 0.3, 1, 3, or 5 mg/kg. Late onset PSA
responses (declines >50%) were seen in these five patients
with response durations of 6.7, 8.6, 9.5, 13.8 (ongoing), and
23.1 months. Four of these patients had stable disease on
bone scan for at least 12 months and up to 21 months. Five
of six patients at the higher ipilimumab doses (3 and 5 mg/
kg) developed grade 2 or 3 ipilimumab-related AEs.
Follow-up on the 16 expansion cohort patients, as well as
a larger clinical trial with an optimal dose of ipilimumab,
will provide more robust data on safety and clinical activity
in prostate cancer.
In a phase I dose escalation trial of ipilimumab (3, 5, and
10 mg/kg) alone and in combination with single fraction
radiotherapy in patients with metastatic CRPC, 6 of 26
treated patients (23%) had a confirmed >50% PSA decline.
One of the seven patients with measurable disease had a
partial response in nodal metastases and achieved an
undetectable PSA after treatment with 10 mg/kg [38]. A
phase II study of 10 mg/kg ipilimumab alone or with
radiation in 45 patients with CRPC reported 10 patients
(22%) with confirmed PSA declines ≥50% [39]. The
median time to PSA decline was 5.7 weeks and the median
duration of PSA decline was 23 weeks. One patient dosed
with ipilimumab alone experienced a PSA level ≤0.05 ng/
ml, as well as complete responses of bone, nodal, and
prostate lesions which continued for 54+ and 84+weeks,
respectively. Ipilimumab-associated AEs were experienced
in 17 patients (38%) and included diarrhea/colitis, rash/
pruritus, hepatitis, and endocrinopathy. Eleven patients
(24%) experienced≥grade 3 events (gastrointestinal [9
patients; 20%] and hepatitis [4 patients; 9%]), and all
resolved with corticosteroid and/or infliximab therapy. A
randomized phase III trial comparing combination use of
radiotherapy and ipilimumab to radiotherapy and placebo in
men who have failed docetaxel chemotherapy is currently
underway (NCT00861614).
In a small trial testing the combination of ipilimumab
and a single dose of docetaxel in patients with CRPC, there
was no apparent enhancement of activity by coadministra-
tion of a single dose of docetaxel [52]. However, the
combination of ipilimumab and the chemotherapeutic agent
dacarbazine demonstrated more clinical activity than
ipilimumab in melanoma patients [53], suggesting that the
combination of ipilimumab and chemotherapy may be
clinically beneficial and should be further explored in
prostate cancer.
Challenges to the Development of Novel Therapies
for CRPC
The failures of the clinical trial programs for many drugs in
development for CRPC demonstrate the difficulties in
finding an effective treatment for this disease. For example,
while the oral platinum analog satraplatin initially showed
an improved in PFS of 2.5 to 5.2 months [54], it failed to
demonstrate an OS benefit in a large phase III trial [55].
The endothelin A receptor antagonist atrasentan failed to
show improvement in TTP and median survival times when
compared with placebo [56]. Furthermore, combinations of
docetaxel with other agents have showed either limited
efficacy or unacceptable toxicity. A recent small study of
docetaxel and 10 mg atrasentan reported OS and PFS
comparable to docetaxel and prednisone [57]. The phase II
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Androgen-Independent Prostate Cancer Study of Calcitriol
Enhancing Taxotere-1 (ASCENT-1) study, which investi-
gated the use of docetaxel in combination with the vitamin
D agonist DN-101, failed to achieve its primary endpoint of
improved PSA response rate; however, this study initially
appeared to demonstrate an increased median survival
benefit with combination therapy [58]. A larger ASCENT-
2 study, which began enrolling patients in February 2006,
was halted early and eventually terminated due to the
excessive number of deaths in the treatment arm compared
with the control arm [58]. Lastly, the study of the
combination of docetaxel and the vaccine GVAX was
closed early because of excess deaths in the GVAX
combination arm (as compared with GVAX alone) [27, 58].
The development of an effective therapy for men with
CRPC has been challenged by both the nature of the
disease and by the lack of reliable assessment endpoints to
determine the efficacy of novel agents. For example, less
than half of men with CRPC have measurable target lesions
>2 cm in size. Therefore, it has been recommended that
trials should no longer require that a patient has measurable
lesions (target lesions as defined by Response Evaluation
Criteria in Solid Tumors [RECIST]) for entry [4]. It is also
difficult to determine a favorable outcome in bone, the most
common site of prostate cancer spread. Consequently, there
is a lack of a reliable and identifiable surrogate endpoint for
OS in prostate cancer clinical trials.
The most widely accepted efficacy marker in CRPC
clinical trials is PSA. The PSA level is related to tumor
growth and generally has a positive correlation with tumor
burden; however, a correlation between a given post-
therapy change and true clinical benefit has not been fully
defined. While PSA level itself is not a reliable endpoint,
PSA kinetics (slope, PSA doubling time) may prove to be.
In the search for reliable surrogate endpoints for clinical
trials in prostate cancer, researchers have also evaluated the
following endpoints: CTC count, alkaline phosphatase and
lactate dehydrogenase levels, bone scans, symptoms as-
sessment, and computed/tomography/magnetic resonance
imaging scans.
The second Prostate Cancer Clinical Trials Working
Group (PCWG2) recently reassessed the outcome measures
for clinical trials in prostate cancer. The 2008 guidelines
recommend that outcomes are reported independently for
PSA, imaging, and clinical measures, avoiding grouped
categorizations such as complete or partial response [4].
Changes in PSA should be reported as change from
baseline in a waterfall plot; bone scans are to be reported
as “new lesions” or “no new lesions”; changes in soft tissue
will continue to be assessed by RECIST; and pain is to be
monitored using validated scales. PCWG2 also proposes
that drug evaluation pathways for cytotoxic and non-
cytotoxic agents be developed separately. Cytotoxic drugs
typically produce a decline in PSA and regression of target
lesions, whereas agents that act to slow tumor growth,
inhibit destruction of bone, or inhibit angiogenesis may not.
Thus, PCWG2 recommends two types of phase II trial
objectives: (1) those based on controlling, relieving, or
eliminating disease manifestations that are present when
treatment is initiated and (2) those based on preventing or
delaying future disease manifestations. Following these
recommendations will be critical to ensure the timely and
safe development of novel therapies for CRPC.
Future Directions
While great progress has been made in the treatment of
CRPC, there remains a need for better therapies that are
more effective with fewer side effects. The development of
new therapies for CPRC has been challenged by multiple
setbacks, as trials have failed to demonstrate efficacy (e.g.,
atrasentan) or have been terminated prematurely because of
excessive deaths (e.g., GVAX in the VITAL-2 trial). With
learnings from previous study limitations, ongoing phase III
trials in CRPC (Table I) have been designed with the goals
of improving efficacy and minimizing AEs, as well as
improving outcomes relative to existing standards of care.
A major challenge to the development of new therapeu-
tics for CRPC is the lack of surrogate endpoints. Many
current trials rely on OS as an efficacy measure, an
endpoint that requires much time to assess. Additionally,
as more patients are treated with combination therapies,
which can include up to three different agents, it becomes
more difficult to ascribe from which agent clinical benefit is
derived. It is the authors’ opinion that bone metastasis-free
survival may be an informative surrogate endpoint to
consider in efficacy analysis of treatment regimens in
clinical studies.
Immune monitoring is critical in the assessment of
immunotherapeutic approaches. Although clinical research
to date has not demonstrated conclusive support for
immune monitoring approaches, a variety of bioassaying
techniques exist that may have potential for use in immune
monitoring, including the enzyme-linked immunosorbent
spot assay and cytometry-based tests such as intracellular
cytokine staining. These techniques are starting to be
employed in phase I/II trials to investigate particular
immune monitoring strategies for developmental therapies.
Monitoring the immune system for drug-related AEs is
imperative, as the immunotherapies discussed in this review
present a spectrum of toxicities. For instance, clinical trials
with sipuleucel-T have demonstrated limited toxicity [30],
while ipilimumab use has been reported to have more
systemic side effects due to its mechanism of action [59].
Additionally, for almost all of these therapies, the patient
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population best suited for intervention has not been clearly
defined.
Another challenge is finding the right combination and
timing of therapy for CRPC because of the complexity in
testing each combination and other intellectual property issues.
The dose range for chemotherapy, when combined with
immunotherapy, has proven to be surprisingly low and the
effects are critically dependent on the relative timing of the two
agents. Furthermore, to date, most novel agents such as
immunotherapy have been introduced late in the disease, at a
time when the tumor has already developed multiple mecha-
nisms to evade the immune system. Recent work has identified
a few biochemical markers (PSA doubling time, cancer–testis
antigen and neutral endopeptidase expression, and AR poly-
morphisms) [60–63] that show increased expression in
patients that are likely to develop CRPC. Defining key
biomarkers will help identify patient populations that may
benefit from earlier treatment intervention, as well as patients
that may respond to specific molecular agents.
An additional reason that therapies have failed to meet
efficacy endpoints is because the biology behind the
development and progression of CRPC is not well defined.
Furthermore, preclinical models used to model CRPC are
not representative of the clinical course of the disease. More
research in CRPC, including the development of new cell
lines and prostate tumor models, are needed to test novel
therapies.
Lastly, clinical trial design needs to be improved to
maximize its impact. Trials must be standardized to
compare treatment regimens; for example, if chemotherapy
is to be the comparator arm (instead of placebo), it needs to
be standardized across treatment groups. In addition, the
metrics currently used for measuring response (e.g., PSA
decline) may not correlate with a clinically meaningful
outcome; OS is likely a better primary endpoint to evaluate
clinical activity. The direction of therapy design should be
carefully assessed and reevaluated as our understanding of
the pathology of CRPC and the technology for developing
new therapies evolves. Unlike chemotherapy, immunother-
apy requires time to take effect as a patient’s immune
system must mount a response to the tumor. Thus, trials of
immunotherapeutic agents need to allow for the immune
system response before measuring the antitumor response.
In addition, the use of immunotherapies may require a
somewhat revised set of guidelines with which to evaluate
responses, as this group of agents often demonstrates
response patterns not captured by standard RECIST or
World Health Organization criteria [64].
The addition of immunotherapy to the therapeutic
options for CRPC is likely to greatly improve efficacy
and safety for this difficult-to-treat disease. Combinations
of immunomodulators, vaccines, antibodies, and chemo-
therapy will most likely be needed for the host to mount a
more vigorous antitumor response for patients with ad-
Table I Ongoing phase III trials in CRPC
Clinical Trials.
gov identifier












20 mg/m2 cabazitaxel/prednisone versus
25 mg/m2 cabazitaxel/prednisone
versus docetaxel/prednisone
OS Chemotherapy-naive metastatic CRPC Sanofi-aventis
NCT00887198 Abiraterone acetate/prednisone versus
placebo/prednisone




NCT00638690 Abiraterone acetate/prednisone versus
placebo/prednisone




MDV3100 versus placebo OS Metastatic CRPC post-docetaxel Medivation, Inc.
NCT01212991
(PREVAIL)











OS Metastatic CRPC post-docetaxel Millennium
Pharmaceuticals, Inc.




NCT00861614 Ipilimumab versus placebo, each
following a single dose of RT
OS Metastatic CRPC post-docetaxel Bristol-Myers Squibb
CRPC castration-resistant prostate cancer, OS overall survival, PFS progression-free survival, rPFS radiographic progression-free survival, RT
radiotherapy
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vanced disease. By employing combinations of agents, such
treatment regimens may impact the intratumor balance to
shift in favor of immune response. For example, certain
combinations of immunotherapy with chemotherapy agents
or vaccines may be pivotal in the elimination of immuno-
suppressive regulatory T cells, in turn increasing the ratio in
support of effector T cells to mediate antitumor immunity.
Currently, much work has been focused on enhancing
vaccine therapy by adding another immunotherapy such as a
checkpoint blockade agent or some conventional therapy like
radiation or chemotherapy. However, single-agent checkpoint
blockade has shown dramatic RECIST responses in melano-
ma [64] and more recently in prostate cancer. These recent
findings are a reason to rethink that dogma and instead
investigate how to enhance a checkpoint blockade therapy
(e.g., ipilimumab) by the addition of another checkpoint
blocker, chemotherapy, or radiation. The timing of immuno-
therapy will likely prove crucial; patients will likely respond
better if treated at an earlier time point, before the tumor
develops multiple ways to evade the immune system.
Finding the right combinations and sequences that maximize
efficacy while minimizing toxicity will be challenging and
take extensive and careful research.
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